Loading…
Lobbying Spend
—
Filings
78
Firms Hired
2
Active Period
2016–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling. H.R. 9661/S. 1414 - Expediated Access to Biosimilars Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1843
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling. H.R. 9661/S. 1414 - Expediated Access to Biosimilars Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3269
Biosimilar Red Tape Elimination Act
2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling. H.R. 9661/S. 1414 - Expediated Access to Biosimilars Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5526
Expedited Access to Biosimilars Act
2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling. H.R. 9661/S. 1414 - Expediated Access to Biosimilars Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 9661
Drug Competition Enhancement Act
2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling. H.R. 9661/S. 1414 - Expediated Access to Biosimilars Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 1040
Increasing Transparency in Generic Drug Applications Act
2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling. H.R. 9661/S. 1414 - Expediated Access to Biosimilars Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 1302
Expedited Access to Biosimilars Act
2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling. H.R. 9661/S. 1414 - Expediated Access to Biosimilars Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 1414
Biosimilar Red Tape Elimination Act
2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling. H.R. 9661/S. 1414 - Expediated Access to Biosimilars Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 1954
Skinny Labels, Big Savings Act
2026 · third_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling. H.R. 9661/S. 1414 - Expediated Access to Biosimilars Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 43
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
2026 · second_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1843
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3269
Biosimilar Red Tape Elimination Act
2026 · second_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5526
Drug Competition Enhancement Act
2026 · second_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling.
Client expense: — · Firm income: $60,000
Matched citations: S. 1040
Increasing Transparency in Generic Drug Applications Act
2026 · second_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling.
Client expense: — · Firm income: $60,000
Matched citations: S. 1302
Biosimilar Red Tape Elimination Act
2026 · second_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling.
Client expense: — · Firm income: $60,000
Matched citations: S. 1954
Skinny Labels, Big Savings Act
2026 · second_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling.
Client expense: — · Firm income: $60,000
Matched citations: S. 43
Mikaela Naylon Give Kids a Chance Act
2026 · first_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red-tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; H.R. 1262 - Mikayla Naylon Give Kids a Chance Act. Country of Origin labeling.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1262
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
2026 · first_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red-tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; H.R. 1262 - Mikayla Naylon Give Kids a Chance Act. Country of Origin labeling.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1843
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red-tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; H.R. 1262 - Mikayla Naylon Give Kids a Chance Act. Country of Origin labeling.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3269
Biosimilar Red Tape Elimination Act
2026 · first_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red-tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; H.R. 1262 - Mikayla Naylon Give Kids a Chance Act. Country of Origin labeling.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5526
Drug Competition Enhancement Act
2026 · first_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red-tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; H.R. 1262 - Mikayla Naylon Give Kids a Chance Act. Country of Origin labeling.
Client expense: — · Firm income: $60,000
Matched citations: S. 1040
Increasing Transparency in Generic Drug Applications Act
2026 · first_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red-tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; H.R. 1262 - Mikayla Naylon Give Kids a Chance Act. Country of Origin labeling.
Client expense: — · Firm income: $60,000
Matched citations: S. 1302
Biosimilar Red Tape Elimination Act
2026 · first_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red-tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; H.R. 1262 - Mikayla Naylon Give Kids a Chance Act. Country of Origin labeling.
Client expense: — · Firm income: $60,000
Matched citations: S. 1954
Skinny Labels, Big Savings Act
2026 · first_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red-tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; H.R. 1262 - Mikayla Naylon Give Kids a Chance Act. Country of Origin labeling.
Client expense: — · Firm income: $60,000
Matched citations: S. 43
Mikaela Naylon Give Kids a Chance Act
2025 · fourth_quarter · Firm: MEHLMAN CONSULTING, INC.
Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red-tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; H.R. 1262 - Mikayla Naylon Give Kids a Chance Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1262
Source: Senate LDA